Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cutisanol Pó
- Development stage
- Unknown
- Lead developer
- Millet Roux
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Cutisanol Pó is a topical dermatological powder developed by the Brazilian pharmaceutical company Millet Roux (MR Pharma). It is a combination product containing bismuth subgallate, zinc oxide, and thymol iodide. The formulation acts as an antiseptic and drying agent, creating a protective barrier on the skin to reduce irritation and promote healing. It is primarily indicated for the prevention and treatment of diaper dermatitis, diaper rash, heat rash (prickly heat), eczema, and various other skin irritations. Marketed since 1941, it is approved for both adult and pediatric use and is typically applied to clean, dry skin multiple times daily.
- Brand names
- Cutisanol PóCutisanol Powder
- Other names
- Cutisanol
02
Targets
PEP (Pepsin)
Beyond the preview
Go deeper on Cutisanol Pó.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cutisanol Pó.